Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MP71-MC2-TCR16-3D9
- Development stage
- Phase 2
- Lead developer
- Erasmus MC
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
MP71-MC2-TCR16-3D9 is an autologous T-cell receptor (TCR) engineered T-cell therapy developed by Erasmus University Medical Center (Erasmus MC). The therapy utilizes the MP71 gamma-retroviral vector to transduce a patient's own T cells with a TCR (clone 16-3D9) specific for the MAGE-C2 (Melanoma-associated antigen C2) protein. MAGE-C2 is a cancer-germline antigen that is highly expressed in several cancers, including melanoma and head and neck squamous cell carcinoma, but has limited expression in normal tissues, making it a suitable target for immunotherapy. The TCR recognizes the MAGE-C2-derived peptide ALKDVEERV presented by HLA-A*02:01. This cell therapy is designed to selectively identify and eliminate MAGE-C2-expressing tumor cells through direct cytotoxic activity upon recognition of the peptide-MHC complex.
- Other names
- MAGE-C2 TCR-T cellsMAGE-C-2 TCR-T cellsMAGE-C 2 TCR-T cellsMC2-TCR-TMC-2-TCR-TMC 2-TCR-TMAGE-C2-specific TCR-engineered T cellsMAGE-C-2-specific TCR-engineered T cellsMAGE-C 2-specific TCR-engineered T cells
02
Targets
MAGE-C2/HLA-A*02:01 (Melanoma-associated antigen C2 peptide–major histocompatibility complex)
Beyond the preview
Go deeper on MP71-MC2-TCR16-3D9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MP71-MC2-TCR16-3D9.